RU2018135567A - Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул - Google Patents
Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул Download PDFInfo
- Publication number
- RU2018135567A RU2018135567A RU2018135567A RU2018135567A RU2018135567A RU 2018135567 A RU2018135567 A RU 2018135567A RU 2018135567 A RU2018135567 A RU 2018135567A RU 2018135567 A RU2018135567 A RU 2018135567A RU 2018135567 A RU2018135567 A RU 2018135567A
- Authority
- RU
- Russia
- Prior art keywords
- cell
- changing
- cellular functionality
- functionalized biocompatible
- nanoparticle
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 title claims 13
- 230000001413 cellular effect Effects 0.000 claims 12
- 210000004027 cell Anatomy 0.000 claims 11
- 210000004962 mammalian cell Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 230000000975 bioactive effect Effects 0.000 claims 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- 108091023040 Transcription factor Proteins 0.000 claims 2
- 102000040945 Transcription factor Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 239000012528 membrane Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 101100239628 Danio rerio myca gene Proteins 0.000 claims 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 229910052742 iron Inorganic materials 0.000 claims 1
- 101150111214 lin-28 gene Proteins 0.000 claims 1
- 230000000877 morphologic effect Effects 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/34—Belt retractors, e.g. reels
- B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
- B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
- B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B60—VEHICLES IN GENERAL
- B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
- B60R22/00—Safety belts or body harnesses in vehicles
- B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
- B60R2022/289—Energy-absorption curves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mechanical Engineering (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161550213P | 2011-10-21 | 2011-10-21 | |
| US61/550,213 | 2011-10-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014120465/15A Division RU2014120465A (ru) | 2011-10-21 | 2012-10-22 | Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2018135567A true RU2018135567A (ru) | 2018-11-15 |
Family
ID=48141479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018135567A RU2018135567A (ru) | 2011-10-21 | 2012-10-22 | Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул |
| RU2014120465/15A RU2014120465A (ru) | 2011-10-21 | 2012-10-22 | Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014120465/15A RU2014120465A (ru) | 2011-10-21 | 2012-10-22 | Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9675708B2 (enExample) |
| EP (2) | EP3400956A1 (enExample) |
| JP (3) | JP2014532628A (enExample) |
| KR (3) | KR20190077124A (enExample) |
| CN (2) | CN104094119A (enExample) |
| AU (3) | AU2012325723A1 (enExample) |
| BR (1) | BR112014009753B1 (enExample) |
| CA (2) | CA2938661A1 (enExample) |
| HK (1) | HK1201089A1 (enExample) |
| IN (1) | IN2014DN03224A (enExample) |
| MX (3) | MX367656B (enExample) |
| RU (2) | RU2018135567A (enExample) |
| SG (2) | SG10201601746TA (enExample) |
| WO (1) | WO2013059831A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104094119A (zh) * | 2011-10-21 | 2014-10-08 | 斯特姆詹尼克斯公司 | 用于胞内传递生物活性分子的官能化纳米粒子 |
| CN110339339A (zh) | 2013-03-01 | 2019-10-18 | 康德生物医疗技术公司 | 治疗线粒体疾病的方法 |
| CN115990242A (zh) * | 2013-03-01 | 2023-04-21 | 康德生物医疗有限公司 | 预防或治疗巴斯综合征的方法和组合物 |
| CA2916977A1 (en) | 2013-06-26 | 2014-12-31 | Stealth Biotherapeutics Corp | Methods and compositions for detecting and diagnosing diseases and conditions |
| US11306326B2 (en) | 2013-08-23 | 2022-04-19 | Rutgers, The State University Of New Jersey | Biologically active synthetic nanoparticle constructs and methods of use thereof |
| US10100332B2 (en) | 2013-08-23 | 2018-10-16 | Rutgers, The State University Of New Jersey | Biologically active synthetic nanoparticle constructs and methods of use thereof |
| CN106414723A (zh) * | 2014-02-10 | 2017-02-15 | 纳维基因股份有限公司 | 细胞调节纳米组合物及使用方法 |
| CN105440112A (zh) * | 2015-12-07 | 2016-03-30 | 国家纳米科学中心 | 多肽-白蛋白偶联药物、其制备方法及应用 |
| WO2017210666A2 (en) * | 2016-06-03 | 2017-12-07 | Stemgenics, Inc. | Functionalized nanoparticles for the intracellular delivery of biologically active molecules and methods for their manufacture and use |
| US20190224335A1 (en) * | 2016-06-03 | 2019-07-25 | Stemgenics, Inc. | Direct reprogramming of a human somatic cell to a selected (predetermined) differentiated cell with functionalized nanoparticles |
| WO2018071572A1 (en) * | 2016-10-11 | 2018-04-19 | Stemgenics, Inc. | Nanoparticles functionalized with gene editing tools and related methods |
| US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
| JP2020504177A (ja) * | 2017-01-04 | 2020-02-06 | ナノティックス，エルエルシー | 捕捉粒子をアセンブルするための方法 |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| US11701433B2 (en) | 2017-06-05 | 2023-07-18 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
| WO2019099685A1 (en) | 2017-11-15 | 2019-05-23 | Rutgers, The State University Of New Jersey | Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof |
| CN108287235B (zh) * | 2018-02-07 | 2021-03-09 | 常州天地人和生物科技有限公司 | 一种高效、稳定的磁性免疫微球的制备和应用 |
| US20200326325A1 (en) | 2019-04-12 | 2020-10-15 | Lisa Diamond | Nanosensor chip with compound nanopores |
| CN112111042B (zh) * | 2019-06-21 | 2024-04-05 | 康码（上海）生物科技有限公司 | 一种生物磁性微球及其制备方法和使用方法 |
| CN110642876A (zh) * | 2019-10-10 | 2020-01-03 | 南京市口腔医院 | 半胱氨酸修饰金纳米颗粒和制备方法、应用及促进骨组织再生产品 |
| CN112472685B (zh) * | 2020-12-10 | 2023-03-24 | 哈尔滨工业大学 | 一种杂化中性粒细胞机器人的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0014252A (pt) * | 1999-09-14 | 2002-11-19 | Biomedical Apherese Systeme Gm | Nanopartìculas magnéticas tendo atividade bioquìmica, método para sua produção e seus usos |
| US7329638B2 (en) * | 2003-04-30 | 2008-02-12 | The Regents Of The University Of Michigan | Drug delivery compositions |
| WO2005080598A1 (ja) * | 2004-02-19 | 2005-09-01 | Dainippon Sumitomo Pharma Co., Ltd. | 体細胞核初期化物質のスクリーニング方法 |
| EP1957045A2 (en) * | 2005-03-14 | 2008-08-20 | Board of Regents, The University of Texas System | Bioactive fus1 peptides and nanoprticle-polypeptide complexes |
| CN101389314A (zh) | 2005-03-14 | 2009-03-18 | 得克萨斯大学体系董事会 | 生物活性fus1肽和纳米颗粒-多肽复合物 |
| US20110182805A1 (en) * | 2005-06-17 | 2011-07-28 | Desimone Joseph M | Nanoparticle fabrication methods, systems, and materials |
| EP2099496A2 (en) * | 2006-12-08 | 2009-09-16 | Massachusetts Institute of Technology | Delivery of nanoparticles and/or agents to cells |
| US20080166412A1 (en) | 2007-01-02 | 2008-07-10 | Kiminobu Sugaya | Methods and materials for stimulating proliferation of stem cell |
| KR100925689B1 (ko) * | 2007-07-25 | 2009-11-10 | 한국생명공학연구원 | 항체와 나노입자를 세포 내로 동시에 전달할 수 있는다기능성 단백질 |
| WO2009035541A1 (en) | 2007-09-10 | 2009-03-19 | Merck & Co., Inc. | Method of treating inherited severe neutropenia |
| KR100951719B1 (ko) * | 2007-10-02 | 2010-04-07 | 재단법인서울대학교산학협력재단 | 세포투과성 펩타이드와 형광표지 자성나노입자의 복합체 및그 용도 |
| AU2008329562A1 (en) * | 2007-11-30 | 2009-06-04 | Cytomatrix Pty Ltd | Methods of inducing pluripotency involving Sox2 protein |
| CA2713872A1 (en) | 2008-02-21 | 2009-08-27 | Burnham Institute For Medical Research | Methods and compositions related to peptides and proteins with c-terminal elements |
| EP2641911A3 (en) * | 2008-12-23 | 2014-01-01 | Vivoscript, Inc. | Compositions and methods for re-programming cells without genetic modification |
| DK2417262T3 (da) * | 2009-04-07 | 2015-06-22 | Dow Agrosciences Llc | Nanopartikelmedieret tilførsel af sekvensspecifikke nukleaser |
| CN104094119A (zh) * | 2011-10-21 | 2014-10-08 | 斯特姆詹尼克斯公司 | 用于胞内传递生物活性分子的官能化纳米粒子 |
-
2012
- 2012-10-22 CN CN201280063870.2A patent/CN104094119A/zh active Pending
- 2012-10-22 EP EP18160010.7A patent/EP3400956A1/en not_active Withdrawn
- 2012-10-22 EP EP12842115.3A patent/EP2769217A4/en not_active Withdrawn
- 2012-10-22 HK HK15101563.8A patent/HK1201089A1/xx unknown
- 2012-10-22 IN IN3224DEN2014 patent/IN2014DN03224A/en unknown
- 2012-10-22 CA CA2938661A patent/CA2938661A1/en not_active Abandoned
- 2012-10-22 RU RU2018135567A patent/RU2018135567A/ru not_active Application Discontinuation
- 2012-10-22 SG SG10201601746TA patent/SG10201601746TA/en unknown
- 2012-10-22 CA CA2853128A patent/CA2853128C/en active Active
- 2012-10-22 KR KR1020197018256A patent/KR20190077124A/ko not_active Ceased
- 2012-10-22 CN CN201610644097.9A patent/CN106822868A/zh active Pending
- 2012-10-22 RU RU2014120465/15A patent/RU2014120465A/ru unknown
- 2012-10-22 BR BR112014009753-4A patent/BR112014009753B1/pt not_active IP Right Cessation
- 2012-10-22 MX MX2018002306A patent/MX367656B/es unknown
- 2012-10-22 KR KR20147010620A patent/KR20150001711A/ko not_active Ceased
- 2012-10-22 KR KR1020207010401A patent/KR20200040924A/ko not_active Ceased
- 2012-10-22 WO PCT/US2012/061391 patent/WO2013059831A1/en not_active Ceased
- 2012-10-22 US US14/353,280 patent/US9675708B2/en active Active - Reinstated
- 2012-10-22 MX MX2014004778A patent/MX2014004778A/es unknown
- 2012-10-22 SG SG11201401658SA patent/SG11201401658SA/en unknown
- 2012-10-22 JP JP2014537369A patent/JP2014532628A/ja not_active Withdrawn
- 2012-10-22 AU AU2012325723A patent/AU2012325723A1/en not_active Abandoned
-
2014
- 2014-04-21 MX MX2018010696A patent/MX2018010696A/es unknown
-
2017
- 2017-06-30 JP JP2017128822A patent/JP6560302B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-31 AU AU2018203848A patent/AU2018203848A1/en not_active Abandoned
- 2018-09-03 JP JP2018164676A patent/JP2018184485A/ja active Pending
-
2020
- 2020-08-27 AU AU2020223737A patent/AU2020223737A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018203848A1 (en) | 2018-06-21 |
| SG10201601746TA (en) | 2016-04-28 |
| RU2014120465A (ru) | 2015-11-27 |
| MX367656B (es) | 2019-08-29 |
| BR112014009753B1 (pt) | 2020-09-15 |
| WO2013059831A1 (en) | 2013-04-25 |
| CN104094119A (zh) | 2014-10-08 |
| JP2017165781A (ja) | 2017-09-21 |
| US20140342004A1 (en) | 2014-11-20 |
| EP2769217A4 (en) | 2015-06-03 |
| JP2018184485A (ja) | 2018-11-22 |
| IN2014DN03224A (enExample) | 2015-05-22 |
| US9675708B2 (en) | 2017-06-13 |
| SG11201401658SA (en) | 2014-07-30 |
| CN106822868A (zh) | 2017-06-13 |
| MX2018010696A (es) | 2020-09-02 |
| JP6560302B2 (ja) | 2019-08-14 |
| JP2014532628A (ja) | 2014-12-08 |
| KR20190077124A (ko) | 2019-07-02 |
| KR20150001711A (ko) | 2015-01-06 |
| CA2853128A1 (en) | 2013-04-25 |
| CA2853128C (en) | 2016-09-27 |
| AU2012325723A1 (en) | 2014-05-15 |
| HK1201089A1 (en) | 2015-08-21 |
| MX2014004778A (es) | 2014-10-17 |
| AU2020223737A1 (en) | 2020-09-17 |
| KR20200040924A (ko) | 2020-04-20 |
| CA2938661A1 (en) | 2013-04-25 |
| EP2769217A1 (en) | 2014-08-27 |
| BR112014009753A2 (pt) | 2017-04-25 |
| EP3400956A1 (en) | 2018-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018135567A (ru) | Функционализированные наночастицы для внутриклеточной доставки биологически активных молекул | |
| JP2014532628A5 (enExample) | ||
| Wang et al. | Recent advances in the fabrication, functionalization, and bioapplications of peptide hydrogels | |
| Yang et al. | Neural tissue engineering: the influence of scaffold surface topography and extracellular matrix microenvironment | |
| Liu et al. | Alginate/gelatin‐based hydrogel with soy protein/peptide powder for 3D printing tissue‐engineering scaffolds to promote angiogenesis | |
| Wang et al. | Ultrashort peptides and hyaluronic acid-based injectable composite hydrogels for sustained drug release and chronic diabetic wound healing | |
| ES2860023T3 (es) | Fabricación de constructos elásticos tridimensionales escalables | |
| WO2015080670A9 (en) | Novel ultrashort hydrophobic peptides that self-assemble into nanofibrous hydrogels and their uses | |
| Tsai et al. | Electrospun chitosan–gelatin–polyvinyl alcohol hybrid nanofibrous mats: Production and characterization | |
| Ranucci et al. | Polyamidoamines: Versatile bioactive polymers with potential for biotechnological applications | |
| EP2615105A4 (en) | CELL PERMEABLE PEPTIDE, BIOACTIVE PEPTIDE CONJUGATE, AND USE THEREOF FROM HUMAN CELLS | |
| US20200155726A1 (en) | A composite, scaffold and applications thereof | |
| Jan et al. | Silicification of genipin-cross-linked polypeptide hydrogels toward biohybrid materials and mesoporous oxides | |
| Maturavongsadit et al. | Adhesive peptides conjugated PAMAM dendrimer as a coating polymeric material enhancing cell responses | |
| Yun et al. | Aligned skeletal muscle assembly on a biofunctionalized plant leaf scaffold | |
| Roberts et al. | Cell derived extracellular matrix fibers synthesized using sacrificial hollow fiber membranes | |
| Kang et al. | Integrating synthetic polypeptides with innovative material forming techniques for advanced biomedical applications | |
| Tonazzini et al. | Neuregulin 1 functionalization of organic fibers for Schwann cell guidance | |
| Mao et al. | Cellular uptake of single-walled carbon nanotubes in 3D extracellular matrix-mimetic composite collagen hydrogels | |
| Rodriguez-Velazquez et al. | Enhanced cell affinity of chitosan membranes mediated by superficial cross-linking: A straightforward method attainable by standard laboratory procedures | |
| Kindi et al. | Effect of metal ions on the physical properties of multilayers from hyaluronan and chitosan, and the adhesion, growth and adipogenic differentiation of multipotent mouse fibroblasts | |
| CN101319245A (zh) | 鱼胶原蛋白肽纳滤分子量分级技术 | |
| Cheng et al. | Interfacial assembly of free-standing polymer-phenolic films for antibacterial and Antiultraviolet applications | |
| Salas-Ambrosio et al. | Electrospinning Lysine-Polypeptide Copolymers: Creating Microfiber Meshes for Biomedical Applications | |
| Rosellini et al. | Molecularly imprinted nanoparticles with recognition properties towards a laminin H–Tyr–Ile–Gly–Ser–Arg–OH sequence for tissue engineering applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20151223 |